CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 136 enrolled
Drug / intervention
Pamiparib +1 moredrug
Likely dose
Pamiparib 60 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03427814
NCT03427814Phase 2Completed
CompareCT.gov

A Phase 2, Double-blind, Randomized Study of BGB-290 Versus Placebo as Maintenance Therapy in Patients With Inoperable Locally Advanced or Metastatic Gastric Cancer That Responded to Platinum-based First-line Chemotherapy

BeiGene·interventional·Posted Feb 9, 2018·Updated Oct 26, 2024

In Brief

A Phase 2 clinical trial evaluating Pamiparib and Placebo for Advanced or Inoperable Gastric Cancer. Completed, enrolled 136 participants across 65 sites in 16 countries.

Detailed Summary

This study enrolled participants with previously-treated advanced or inoperable gastric cancer who have responded to first line platinum therapy into two treatment arms. In Arm A participants received BGB-290; in Arm B participants received placebo. The purpose of this study is to show that BGB-290 (pamiparib) (versus placebo) will improve progression-free survival (PFS) in participants with advanced or inoperable gastric cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced or Inoperable Gastric Cancer
CountriesAustralia, Belgium, China, Czechia, France, Georgia, Hong Kong, Hungary, Japan, Poland, Russia, Singapore, Spain, Taiwan, United Kingdom, United States
Collaborators--

Timeline

Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedFeb 9, 2018
Enrollment StartJul 3, 2018
Primary CompletionJun 18, 2020
Study CompletionJan 3, 2023
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 8.4 years ago

Interventions

Pamiparibdrug

60 mg orally twice daily

Placebodrug

60 mg orally twice daily